文献速递乳腺骨肌技术与安全PETMRCT

18-FDG-PET/MR与PET/CT对乳腺癌N期和M期分期的诊断性能比较

What is the diagnostic performance of 18-FDG-PET/MR compared to PET/CT for the N- and M- staging of breast cancer?
PubMed 文献 · Eur Radiol · 2018-09-28

本研究纳入80例连续乳腺癌分期患者,比较18-FDG-PET/MR与PET/CT对N期和M期的诊断性能。按患者分析两者敏感度和特异度相似;按病灶分析PET/MR对骨转移及全部病灶的敏感度优于PET/CT,但特异度较低。

要点

  • 按患者分析,PET/MR与PET/CT对乳腺癌N期和M期的诊断性能相似。
  • 按病灶分析,PET/MR对骨转移的敏感度0.924高于PET/CT的0.6923(P=0.0034)。
  • 按病灶分析,PET/MR对全部病灶的敏感度0.89高于PET/CT的0.77(P=0.0013),特异度0.96低于PET/CT的0.98(P=0.0075)。

核心结论

  • 读者信心、读者间一致性和按患者分析的诊断性能在PET/MR与PET/CT之间相似;但按病灶分析,PET/MR对全部病灶的敏感度更优而特异度较低。

研究设计与样本

  • 两位对临床/随访资料设盲的独立读者回顾性阅片,纳入80例连续患者的PET/MR和PET/CT检查,用于初诊或复发乳腺癌分期,平均年龄48±12.9岁。

诊断标准与关键数值

  • 参考标准包括病理和/或随访>12个月;按患者分析PET/MR与PET/CT的敏感度和特异度相似(P>0.05)。

临床应用与阅片要点

  • 按病灶分析,PET/MR对骨转移的敏感度0.924高于PET/CT的0.6923(P=0.0034),对全部病灶的敏感度0.89高于PET/CT的0.77(P=0.0013),但特异度0.96低于PET/CT的0.98(P=0.0075)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To compare the diagnostic performance of 18-FDG-PET/MR and PET/CT for the N- and M- staging of breast cancer.

METHODS AND MATERIALS: Two independent readers blinded to clinical/follow-up data reviewed PET/MR and PET/CT examinations performed for initial or recurrent breast cancer staging in 80 consecutive patients (mean age = 48 ± 12.9 years). The diagnostic confidence for lesions in the contralateral breast, axillary/internal mammary nodes, bones and other distant sites were recorded. Sensitivity, specificity, positive (PPV) and negative predictive values (NPV) were calculated. The standard of reference included pathology and/or follow-up > 12 months.

RESULTS: Nine of 80 patients had bone metastases; 13/80 had other distant metastases, 44/80 had axillary, 9/80 had internal mammary and 3/80 had contralateral breast tumours. Inter-reader agreement for lesions was excellent (weighted kappa = 0.833 for PET/CT and 0.823 for PET/MR) with similar reader confidence for the two tests (ICC = 0.875). In the patient-per-patient analysis, sensitivity and specificity of PET/MRI and PET/CT were similar (p > 0.05). In the lesion-per-lesion analysis, the sensitivity of PET/MR and PET/CT for bone metastases, other metastases, axillary and internal mammary nodes, contralateral tumours and all lesions together was 0.924 and 0.6923 (p = 0.0034), 0.923 and 0.923 (p = 1), 0.854 and 0.812 (p = 0.157), 0.9 and 0.9 (p = 1), 1 and 0.25 (p = 0.083), and 0.89 and 0.77 (p = 0.0013) respectively. The corresponding specificity was 0.953 and 1 (p = 0.0081), 1 and 1 (p = 1), 0.893 and 0.92 (p = 0.257), 1 and 1 (p = 1), 0.987 and 0.99 (p = 1) and 0.96 and 0.98 (p = 0.0075) respectively.

CONCLUSIONS: Reader confidence, inter-reader agreement and diagnostic performance per patient were similar with PET/MR and PET/CT. However, for all lesions together, PET/MR had a superior sensitivity and lower specificity in the lesion-per-lesion analysis.

KEY POINTS: • N and M breast cancer staging performance of PET/MR and PET/CT is similar per patient. • In a lesion-per-lesion analysis PET/MR is more sensitive than PET/CT especially for bone metastasis. • Readers' diagnostic confidence is similar for both tests.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Botsikas D, Bagetakos I, Picarra M, et al. What is the diagnostic performance of 18-FDG-PET/MR compared to PET/CT for the N- and M- staging of breast cancer? Eur Radiol. 2018. PMID: 30267154. doi:10.1007/s00330-018-5720-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。